MUC1 is a promising therapeutic target for prostate cancer therapy

Current Cancer Drug Targets

Volumn 7, Issue 3, 2007, Pages 259-271

  Li, Y ^a,b   Cozzi, P J ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Immunotherapy; Metastasis; MUC1; Prostate cancer; Tumor associated antigen

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID MONOCLONAL ANTIBODY Y 90; BLP25 LIPOSOME VACCINE; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; IMMUNOMODULATING AGENT; INTERLEUKIN 2; MODIFIED VACCINIA ANKARA VECTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 214D4; MONOCLONAL ANTIBODY B27.29; MONOCLONAL ANTIBODY BRE3; MONOCLONAL ANTIBODY C595 BI 213; MONOCLONAL ANTIBODY C595 I 111; MONOCLONAL ANTIBODY C595 TC 99M; MONOCLONAL ANTIBODY CCE831; MONOCLONAL ANTIBODY HMFG1; MONOCLONAL ANTIBODY HMFG2; MONOCLONAL ANTIBODY M170; MONOCLONAL ANTIBODY M170 Y 90; MONOCLONAL ANTIBODY MY.1E12; MONOCLONAL ANTIBODY SC 7313; MUCIN 1; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VACCINE; VACCINIA VIRUS VECTOR; VIRUS VECTOR;

ANGIOGENESIS; APOPTOSIS; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CARCINOMA CELL; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE ESCALATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE STRUCTURE; GENOTOXICITY; GLYCOSYLATION; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPH NODE METASTASIS; METASTASIS; MICROMETASTASIS; NONHUMAN; PAIN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN TARGETING; RADICAL RETROPUBIC PROSTATECTOMY; RADIOIMMUNOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SMALLPOX; TRANSURETHRAL RESECTION; TUMOR CELL; UNSPECIFIED SIDE EFFECT; VARIABLE NUMBER OF TANDEM REPEAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CA-15-3 ANTIGEN; DRUG DELIVERY SYSTEMS; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 34247890143     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907780618338     Document Type: Review

References (156)

1. Jemal, A.; Murray, T.; Ward, E.; Samuels, A.; Tiwari, R. C.; Ghafoor, A.; Feuer, E. J.; Thun, M. J. Cancer statistics, 2005.
2. CA Cancer J. Clin. 2005, 55, 10-30.
3. Roberts, W. W.; Bergstralh, E. J.; Blute, M. L.; Slezak, J. M.; Carducci, M.; Han, M.; Epstein, J. I.; Eisenberger, M. A.; Walsh, P. C.; Partin, A. W. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001, 57, 1033-1037.
4. Carroll, P. R.; Kantoff, P. W.; Balk, S. P.; Brown, M. A.; D'Amico, A. V.; George, D. J.; Grossfeld, G. D.; Johnson, C. S.; Kelly, W. K.; Klotz, L.; Lee, W. R.; Lubeck, D. P.; Mcleod, D. G.; Oh, W. K.; Pollack. A.; Sartor, O.; Smith, M. R.; Hart, C. Overview consensus statement: newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002, 60(suppl 3), 1-6.
5. Tu, S. M.; Millikan, R. E.; Mengistu, B.; Delpassand, E. S.; Amato, R. J.; Pagliaro, L. C.; Daliani, D.; Papandreou, C. N.; Smith, T. L.; Kim, J.; Podoloff, D. A.; Logothetis, C. J. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet 2001, 357, 336-341.
6. Soerdjbalie-Maikoe, V.; Pelger, R. C. M.; Lycklama à Nijeholt, G. A.; Arndt, J. M.; Zwinderman, A. H.; Papapoulos, S. E.; Hamdy, N. A. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur. J. Nucl. Med. 2002, 29, 494-498.
7. Beer, T. M.; El-Geneidi, M.; Eilers, K. M. Docetaxel (Taxotere) in the treatment of prostate cancer. Exp. Rev. Anticancer Ther. 2003, 3, 261-268.
8. Tannock, I. F.; Wit, R. D.; Berry, W. R.; Horti, J.; Pluzanska, A.; Chi, K. N.; Oudard, S.; Theodore, C.; James, N. D.; Turesson, I.; Rosenthal, M. A.; Eisenberger, M. A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351, 1502-1512.
9. Lara, P. N. Jr.; Kung, H. J.; Gumerlock, P. H.; Meyers, F. J. Molecular biology of prostate carcinogenesis. Crit. Rev. Oncol. Hematol. 1999, 32, 197-208.
10. Hollingsworth, M. A.; Swanson, B. J. Mucins in cancer: Protection and control of the cell surface. Nat. Rev. 2004, 4, 45-60.
11. Moniaux, N.; Escande, F.; Porchet, N.; Aubert, J. P.; Batra, S. K. Structural organization and classification of the human mucin genes. Front. Biosci. 2001, 6, D1192-D1206.
12. Legrier, M. E.; Pinieux, G. D.; Boye, K.; Arvelo, F.; Judde, J. G.; Fontaine, J. J.; Bara, J.; Poupon, M. F. Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft. Br. J. Cancer 2004, 90, 720-727.
13. Braga, V. M.; Pemberton, L. F.; Duhig, T.; Gendler, S. J. Spatial and temporal expression of an epithelial mucin, Muc-1, during mouse development. Development 1992, 115, 427-437.
14. Patton, S.; Gendler, S. J.; Spicer, A. P. The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim. Biophys. Acta 1995, 1241, 407-423.
15. Gendler, S. J.; Burgart, L. J.; Duhig, T.; Lamport. D.; White, R.; Parker, M.; Taylor-Papadimitriou, J. Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. Proc. Natl. Acad. Sci. USA 1987, 84, 6060-6064.
16. Williams, S. J.; McGuckin, M. A.; Gotley, D. C.; Eyre, H. J.; Sutherland, G. R.; Antalis, T. M. Two novel mucin genes down-regulated in colorectal cancer identified by differential display. Cancer Res. 1999, 59, 4083-4089.
17. Li, Y.; Liu, D.; Chen, D.; Kharbanda, S.; Kufe, D. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 2003, 22, 6107-6110.
18. Avichezer, D.; Taylor-Papadimitriou, J.; Arnon, R. A short synthetic peptide (DTRPAP) induces anti-mucin (MUC-1) antibody, which is reactive with human ovarian and breast cancer cells. Cancer Biochem. Biophys. 1998, 16, 113-128.
19. Nacht, M.; Ferguson, A.; Zhang, W.; Petroziello, J.; Cook, B.; Hong, G. Y.; Maguir, S.; Riley, D.; Coppola, G.; Landes, G.; Madden, S.; Sukumar, S. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res. 1999, 59, 5464-5470.
20. Rakha, E. A.; Boyce, R. W.; Abd El-Rehim, D.; Kurien, T.; Green, A. R.; Paish, E. C.; Robertson, J. F.; Ellis, I. O. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Modern Pathol. 2005, 18, 1295-1304.
21. Dong, Y.; Walsh, M. D.; Cummings, M. C.; Wright, R. G.; Khoo, S. K.; Parsons, P. G.; McGuckin, M. A. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J. Pathol. 1997, 183, 311-317.
22. Drapkin, R.; Crum, C. P.; Hecht, J. L. Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. Hum. Pathol. 2004, 35, 1014-1021.
23. Hinoda, Y.; Ikematsu, Y.; Horinochi, M.; Sato, S.; Yamamoto, K.; Nakano, T.; Fukui, M.; Suehiro, Y.; Hamanaka, Y.; Nishikawa, Y.; Kida, H.; Waki, S.; Oka, M.; Imai, K.; Yonezawa, S. Increased expression of MUC1 in advanced pancreatic cancer. J. Gastroenterol. 2003, 38, 1162-1166.
24. Qu, C. F.; Li. Y.; Song, Y. J.; Rizvi, S. M. A.; Raja, C.; Zhang, D.; Samra, J.; Smith, R.; Perkins, A. C.; Apostolidis, C.; Allen, B. J. MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate. Br. J. Cancer 2004, 91, 2086-2093.
25. Baldus, S. E.; Monig, S. P.; Huxel, S.; Landsberg, S.; Hanisch, F. G.; Engelmann, K.; Schneider, P. M.; Thiele, J.; Holscher, A. H.; Dienes, H. P. MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin. Cancer Res. 2004, 10, 2790-2796.
26. Guddo, F.; Giatromanolaki, A.; Patriarca, C.; Hilkens, J.; Reina, C.; Alfano, R. M.; Vignola, A. M.; Koukourakis, M. I.; Gambacorta, M.; Pruneri, G.; Coggi, G.; Bonsignore, G. Depolarized expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression. Anticancer Res. 1998, 18(3B), 1915-1920.
27. Suzuki, H.; Shoda, J.; Kawamoto, T.; Shinozaki, E.; Miyahara, N.; Hotta, S.; Iizuka, Y.; Nakahara, A.; Tanaka, N.; Yanaka, A.; Irimura, T. Expression of MUC1 recognized by monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinoma. Clin. Exp. Metastas. 2004, 21, 321-329.
28. Hughes, O. D. M.; Denley, H.; Kunkler, R. B.; Denton, G.; Price, M. R.; Perkins, A. C.; Bishop. M.C. MUC1 mucin expression in transitional cell carcinoma of the bladder. J. Urol. Pathol. 2000, 12, 179-191.
29. Lee, H. S.; Lee, H. K.; Kim, H. S.; Yang, H. K.; Kim, W. H. Tumour suppressor gene expression correlates with gastric cancer prognosis. J. Pathol. 2003, 200, 39-46.
30. Cozzi, P. J.; Wang, J.; Delprado, W.; Perkins, A. C.; Allen, B. J.; Russell, P. J.; Li. Y. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin. Exp. Metastas. 2005, 22, 565-573.
31. Price, M. R.; Hudeez, F.; O'Sullivan, C.; Baldwin, R. W.; Edwards, P. M.; Tendler, S. J. B. Immunological and structural features of the protein core of human polymorphic epithelial mucin. Mol. Immunol. 1990, 27, 795-802.
32. Ligtenberg, M. J.; Kruijshaar, L.; Buijs, F.; van Meijer, M.; Litvinov, S. V.; Hilkens J. Cell-associated episialin is a complex containing two proteins derived from a common precursor. J. Biol. Chem. 1992, 267, 6171-6177.
33. Gendler, S.; Taylor-Papadimitriou, J.; Duhig, T.; Rothbard, J.; Burchell, J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J. Biol. Chem. 1988, 263, 12820-12823.
34. Siddiqui, J.; Abe, M.; Hayes, D.; Shani, E.; Yunis, E.; Kufe, D. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinomaassociated antigen. Proc. Natl. Acad. Sci. USA 1988, 85, 2320-2323.
35. Merlo, G. R.; Siddiqui. J.; Cropp, C. S.; Liscia, D. S.; Lidereau, R.; Callahan, R.; Kufe, D. W. Frequent alteration of the DF3 tumorassociated antigen gene in primary human breast carcinomas. Cancer Res. 1989, 49, 6966-6971.
36. Gendler, S. J.; Lancaster, C. A.; Taylor-Papadimitriou, J.; Duhig, T.; Peat, N.; Burchell, J.; Pemberton, L.; Lalani, E. N.; Wilson, D. Molecular cloning and expression of the human tumour-associated polymorphic epithelial mucin, PEM. J. Biol. Chem. 1990, 265, 15286-15293.
37. Baeckstrom, D.; Hansson, G. C.; Nilsson, O.; Johansson, C.; Gendler, S. J.; Lindholm, L. Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins. J. Biol. Chem. 1991, 266, 21537-21547.
38. Brockhausen, I.; Yang, J. M.; Burchell, J.; Whitehouse, C.; Taylor-Papadimitriou, J. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur. J. Biochem. 1995, 233, 607-617.
39. Burchell, J.; Poulsom, R.; Hanby, A.; Whitehouse, C.; Cooper, L.; Clausen, H.; Miles, D.; Taylor-Papadimitriou, J. An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology 1999, 9, 1307-1311.
40. Gendler, S. J.; Spicer, A. P.; Lalani, E. N.; Duhig, T.; Peat, N.; Burchell, J.; Pemberton, L.; Boshell, M.; Taylor-Papadimitriou, J. Structure and biology of a carcinoma-associated mucin, MUC1. Am. Rev. Respir. Dis. 1991, 144, S42-S47.
41. Hanisch, F. G.; Stadie, T. R.; Deutzmann, F.; Peter-Katalinic, J. MUC1 glycoforms in breastcancer cell line T47D as a model for carcinomaassociated alterations of 0-glycosylation. Eur. J. Biochem. 1996, 236, 318-327.
42. Lan, M. S.; Batra, S. K.; Qi, W. N.; Metzgar, R. S.; Hollingsworth, M. A. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J. Biol. Chem. 1990, 265, 15294-15299.
43. Lan, M. S.; Hollingsworth, M. A.; Metzgar, R. S. Polypeptide core of a human pancreatic tumor mucin antigen. Cancer Res. 1990, 50, 2997-3001.
44. Hanisch, F. G.; Muller, S. MUC1: the polymorphic appearance of a human mucin. Glycobiology 2000, 10, 439-449.
45. Spicer, A. P.; Duhig, T.; Chilton. B. S.; Gendler. S. J. Analysis of mammalian MUC1 genes reveals potential functionally important domains. Mamm. Genom. 1995, 6, 885-888.
46. Zrihan-Licht, S.; Vos, H. L.; Baruch, A.; Elroy-Stein, O.; Sagiv, D.; Keydar, I.; Hilkens, J.; Wreschner, D. H. Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeat, expressed in human breast cancer tissue. Eur. J. Biochem. 1994, 224, 787-795.
47. Smorodinsky, N.; Weiss, M.; Hartmann, M. L.; Baruch, A.; Harness, E.; Yaakobovitz, M.; Keydar, I.; Wreschner, D. H. Detection of a secreted MUC1/SEC protein by MUC1 isoform specific monoclonal antibodies. Biochem. Biophys. Res. Commun. 1996, 228, 115-121.
48. Oosterkamp, H. M.; Scheiner, L.; Stefanova, M. C.; Lioyd, K. O.; Finstad, C. L. Comparison of MUC1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z). Int. J. Cancer 1997, 72, 87-94.
49. Baruch, A.; Hartmann, M.; Zrihan-Licht, S.; Greenstein, S.; Burstein, M.; Keydar, I.; Weiss, M.; Smorodinsky, N.; Wreschner, D. H. Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function. Int. J. Cancer 1997, 71, 741-749.
50. Baruch, A.; Hartmann, M.; Yoeli, M.; Adereth, Y.; Greenstein, S.; Stadler, Y.; Skornik, Y.; Zaretsky, J.; Smorodinsky, N.; Keydar, I.; Wreschner, D. H. The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein. Cancer Res. 1999, 59, 1552-1561.
51. Kohlgraf, K. G.; Gawron, A. J.; Higashi, M.; Meza, J. L.; Burdick, M. D.; Kitajima, S.; Kelly, D. L.; Caffrey, T. C.; Hollingsworth, M. A. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res. 2003, 63, 5011-5020.
52. Denton, G.; Brady, K.; Lo, B. K.; Murray, A.; Graves, C. R.; Hughes, O. D.; Tendler, S. J.; Laughton, C. A.; Price, M. R. Production and characterization of an anti-(MUC1 mucin) recombinant diabody. Cancer Immunol. Immunother. 1999, 48, 29-38.
53. Barratt-Boyes, S. Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol. Immunother. 1996, 43, 142-151.
54. Nehls, V.; Schuchardt, E.; Drenckhahn, D. The effect of fibroblasts, vascular smooth muscle cells, and pericytes on sprout formation of endothelial cells in a fibrin gel angiogenesis system. Microvasc. Res. 1994, 48, 349-363.
55. Cockerill, G. W.; Gamble, J. R.; Vadas, M. A. Angiogenesis: Models and modulators. Int. Rev. Cytol. 1995, 159, 113-160.
56. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
57. Kim, K. J.; Li. B.; Winter, J.; Armanini, M.; Gillett, N.; Phillips, H. S.; Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362, 841-844.
58. Folkman, J.; Watson, K.; Ingber, D.; Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339, 58-61.
59. Weidner, N.; Carroll, P. R.; Flax, J.; Blumenfeid, W.; Folkman. J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 1993, 143, 401-409.
60. Sokoloff, M. H.; Chung, L. M. Targeting angiogenic pathways involving tumor-stromal interaction to treat advanced human prostate cancer. Cancer Metastasis. Rev. 1999, 17, 307-315.
61. Choy, M.; Rafii, S. Role of angiogenesis in the progression and treatment of prostate cancer. Cancer Invest. 2001, 19, 181-191.
62. Borre, M.; Offersen, B. V.; Nerstrom, B.; Overgaard, J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br. J. Cancer 1998, 78, 940-944.
63. Bettencourt, M. C.; Bauer, J. J.; Sesterhenn, I. A.; Connelly, R. R.; Moul, J. W. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J. Urol. 1998, 160, 2459-2465.
64. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell. 2000, 100, 57-70.
65. Folkman, J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 1999, 143, 401-403.
66. Duque, J. L.; Loughlin, K. P.; Adam, R. M.; Kantoff, P. W.; Zurakofski, D.; Freeman, M. R. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999, 54, 523-527.
67. Giatromanolaki, A.; Koukourakis, H. I.; Sivridis, E.; O'Byrne, K.; Cox, G.; Thorpe, P. E.; Gatter. K. C.; Harris, A. L. Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin. Cancer Res. 2000, 6, 1917-1921.
68. Papadopoulos, I.; Sivridis, E.; Giatromanolaki, A.; Koukourakis, M. I. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin. Cancer Res. 2001, 7, 1533-1538.
69. Lapointe, L.; Li, C. D.; Higgins, J. P.; van de Rijn, M.; Bair, E.; Montgomery, K.; Ferrari, M.; Egevad, L.; Rayford, W.; Bergerheim, U.; Ekman, P.; DeMarzo, A. M.; Tibshirani, R.; Botstein, D.; Brown, P. O.; Brooks, J. D.; Pollack, J. R. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. USA 2004, 101, 811-816.
70. Wreschner, D. H.; Hareuveni, M.; Tsartaty, I.; Smorodinsky, N.; Horev, J.; Zaretsky, J.; Kotkes, P.; weiss, M.; Lathe, R.; Dion, A. Human epithelial tumor antigen cDNA sequences. Differential splicing may generate multiple protein forms. Eur. J. Biochem. 1990, 189, 463-473.
71. Pandey, P.; Kharbanda, S.; Kufe, D. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res. 1995, 55, 4000-4003.
72. Zrihan-Licht, S.; Baruch, A.; Elroy-Stein, O.; Keydar, I.; Wreschner, D. H. Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. Cytokine receptor-like molecules. FEBS Lett. 1994, 356, 130-136.
73. Yamamoto, M.; Bharti, A.; Li, Y.; Kufe, D. Interaction of the DF3/MUC1 breast carcinoma-associated antigen and ?-catenin in cell adhesion. J. Biol. Chem. 1997, 272, 12492-12494.
74. Quin, R. J.; McGuckin, M. A. Phosphorylation of the cytoplasmic domain of the MUC1 mucin correlates with changes in cell-cell adhesion. Int. J. Cancer 2000, 87, 499-506.
75. Schroeder, J. A.; Adriance, M. C.; Thompson, M. C.; Camenisch, T. D.; Gendler, S. J. MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 2003, 22, 1324-1332.
76. Li, Y.; Kuwahara, H.; Ren, J.; Wen, G.; Kufe, D. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinomaassociated antigen with GSK3 beta and beta-catenin. J. Biol. Chem. 2001, 276, 6061-6064.
77. Li, Y.; Ren, J.; Yu, W.; Li, Q.; Kuwahara, H.; Yin, L.; Carraway, K. L. 3rd; Kufe, D. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J. Biol. Chem. 2001, 276, 35239-35242.
78. Ren, J.; Li, Y.; Kufe, D. Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J. Biol. Chem. 2002, 277, 17616-17622.
79. Schroeder, J. A.; Thompson, M. C.; Gardner, M. M.; Gendler, S. J. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J. Biol. Chem. 2001, 276, 13057-13064.
80. Li, Y.; Yu, W. H.; Ren, J.; Chen, W.; Huang, L.; Kharbanda, S.; Loda, M.; Kufe, D. Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol. Cancer Res. 2003, 1, 765-775.
81. Kobayashi, M.; Iwamatsu, A.; Shinohara-Kanda, A.; Ihara, S.; Fukui, Y. Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas. Oncogene 2003, 22, 1294-1301.
82. Li, Y.; Kufe, D. The Human DF3/MUC1 carcinoma-associated antigen signals nuclear localization of the catenin p120(ctn). Biochem. Biophys. Res. Commun. 2001, 281, 440-443.
83. Hulsken, J.; Behrens, J.; Birchmeier, W. Tumor-suppressor gene products in cell contacts: the cadherin-APC-armadillo connection. Curr. Opin. Cell. Biol. 1994, 6, 711-716.
84. Wen, Y.; Caffrey, T. C.; Wheelock, M. J.; Johnson, K. R.; Hollingsworth, M. A. Nuclear association of the cytoplasmic tail of muc1 and β-catenin. J. Biol. Chem. 2003, 278, 38029-38039.
85. Li, Y.; Bharti, A.; Chen, D.; Gong, J.; Kufe, D. Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol. Cell. Biol. 1998, 18, 7216-7224.
86. Carraway, K. L.; Ramsauer, V. P.; Haq, B.; Carraway, C. A. C. Cell signaling through membrane mucins. Bioessays 2003, 25, 66-71.
87. Meerzaman, D.; Shaoiro, P. S.; Kim, K. C. Involvement of the MAP kinase ERK2 in MUC1 mucin signalling. Am. J. Phys. Lung Cell. Mol. Physiol. 2001, 281, L86-L91.
88. Liotta, L. A.; Steeg, P. S.; Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991, 64, 327-336.
89. Bramwell, M. E.; Wiseman, G.; Shotton, D. M. Electromicroscopic studies of the CA antigen, epitectin. J. Cell. Sci. 1986, 86, 249-261.
90. Hilkens, J.; Ligtenberg, J. L.; Vos, H. L.; Litvinov, S. Cell membrane associated mucins and their adhesion-modulating property. Trends Biochem. Sci. 1992, 17, 359-363.
91. Osako, M.; Yonezawa, S.; Siddiki, B.; Huang, J.; Ho, J. J.; Kim, Y. S.; Sato, E. Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors. Cancer 1993, 71, 2191-2199.
92. Wesseling, J.; Van der Valk, S. W.; Vos, H. L.; Sonnenberg, A.; Hilkens, J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J. Cell. Biol. 1995, 129, 255-265.
93. Kondo, K.; Kohno, N.; Yokoyama, A.; Hiwada, K. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res. 1998, 58, 2014-2019.
94. Feng, H.; Ghazizadeh, M.; Konishi, H.; Araki, T. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn. J. Clin. Oncol. 2002, 32, 525-529.
95. Wesseling, J.; Van der Valk, S. W.; Hilkens, J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membraneassociated mucin episialin/MUC1. Mol. Biol. Cell. 1996, 7, 565-577.
96. Komatsu, M.; Carraway, C. A.; Fregien, N. L.; Carraway, K. L. Reversible disruption of cell-matrix and cell-cell interactions by overexpression of sialomucin complex. J. Biol. Chem. 1997, 272, 33245-33254.
97. McDermott, K. M.; Crocker, P. R.; Harris, A.; Burdick, M. D.; Hinoda, Y.; Hayashi, T.; Imai, K.; Hollingsworth, M. A. Overexpression of MUC1 reconfigures the binding properties of tumor cells. Int. J. Cancer 2001, 94, 783-791.
98. Zhang, K.; Baeckstrom, D.; Brevinge, H.; Hansson, G. C. Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells. J. Cell. Biochem. 1996, 60, 538-549.
99. Nath, D.; Hartnell, A.; Happerfield, L.; Miles, D. W.; Burchell, J.; Taylor-Papadimitriou, J.; Crocker, P. R. Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counterreceptor for the macrophage-restricted receptor, sialoadhesin. Immunology 1999, 98, 213-219.
100. Brinkman-Van der Linden, E. C.; Varki, A. New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins. J. Biol. Chem. 2000, 275, 8625-8632.
101. Baldus, S. E.; Zirbes, T. K.; Monig, S. P.; Engel, S.; Monaca, E.; Rafiqpoor, K.; Hanisch, F. G.; Hanski, C.; Thiele, J.; Pichlmaier, H.; Dienes, H. P. Histopathological subtypes and prognosis of gastric cancer are correlated with the expression of mucin-associated sialylated antigens: Sialosyl-Lewis(a), Sialosyl-Lewis(x) and sialosyl-Tn. Tumour Biol. 1998, 19, 445-453.
102. Baldus, S. E.; Hanisch, F. G. Biochemistry and pathological importance of mucin-associated antigens in gastrointestinal neoplasia. Adv. Cancer Res. 2000, 79, 201-248.
103. Baldus, S. E.; Monig, S. P.; Hanisch, F. G.; Zirbes, T. K.; Flucke, U.; Oelert, S.; Zilkens, G.; Madejczik, B.; Thiele, J.; Schneider, P. M.; Holscher, A. H.; Dienes, H. P. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma. Histopathology 2002, 40, 440-449.
104. Schwartz, B.; Bresalier, R. S.; Young, K. S. The role of mucin in colon cancer metastasis. Int. J. Cancer 1992, 52, 60-65.
105. Regimbald, L. H.; Pilarski, L. M.; Longenecker, B. M.; Reddish, M. A.; Zimmermann, G.; Hugh, J. C. The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res. 1996, 56, 4244-4249.
106. Kam, J. L.; Regimbald, L. H.; Hilgers, J. H.; Hoffman, P.; Krantz, M. J.; Longenecker, B. M.; Hugh, J. C. MUC1 synthetic peptide inhibitor of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats. Cancer Res. 1998, 58, 5577-5581.
107. Rahn, J. J.; Shen, Q.; Mah, B. K.; Hugh, J. C. MUC1 initiates a calcium signal after ligation by intercellular adhesion molecule-1. J. Biol. Chem. 2004, 279, 29386-29390.
108. Rahn, J. J.; Chow, J. W.; Horne, G. J.; Mah, B. K.; Emerman, J. T.; Hoffman, P.; Hugh, J. C. MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin. Exp. Metastas. 2005, 22, 475-483.
109. Spicer, A. P.; Rowse, G. J.; Lidner, T. K.; Gendler, S. J. Delayed mammary tumor progression in Muc-1 null mice. J. Biol. Chem. 1995, 270, 30093-30101.
110. Kroemer, G.; Reed, J. C. Mitochondrial control of cell death. Nat. Med. 2000, 6, 513-519.
111. Herr, I.; Debatin, K. M. Cellular stress response and apoptosis in cancer therapy. Blood 2001, 98, 2603-2614.
112. Datta, R.; Manome, Y.; Taneja, N.; Boise, L. H.; Weichselbaum, R.; Thompson, C. B.; Slapak, C. A.; Kufe, D. Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell. Growth. Differ. 1995, 6, 363-370.
113. Bunz, F. Cell death and cancer therapy. Curr. Opin. Pharmacol. 2001, 1, 337-341.
114. Li, Y.; Chen, W.; Ren, J.; Yu, W. H.; Li, Q.; Yoshida, K.; Kufe, D. DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7. Cancer Biol. Ther. 2003, 2, 187-193.
115. Wen, Y.; Caffrey, T. C.; Wheelock, M. J.; Johnson, K. R.; Hollingsworth, M. A. Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J. Biol. Chem. 2003, 278, 38029-38039.
116. Ren, J.; Agata, N.; Chen, D.; Li, Y.; Yu, W. H.; Huang, L.; Raina, D.; Chen, W.; Kharbanda, S.; Kufe, D. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 2004, 5, 163-175.
117. Wei, X.; Xu, H.; Kufe, D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell. 2005, 7, 167-178.
118. Chan, A. K.; Lockhart, D. C.; von Bernstorff, W.; Spanjaard, R. A.; Joo, H. G.; Eberlein, T. J.; Goedegebuure, P. S. Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation. Int. J. Cancer 1999, 82, 721-726.
119. van de Wiel-van Kemenade, E.; Ligtenberg, M. J.; de Boer, A. J.; Buijs, F.; Vos, H. L.; Melief, C. J.; Hilkens, J.; Figdor, C. G. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J. Immunol. 1993, 151, 767-776.
120. Agrawal, B.; Krantz, M. J.; Reddish, M. A.; Longenecker, B. M. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nature Med. 1998, 4, 43-49.
121. Rye, P. D.; McGuckin, M. A. MUC1: antibodies and immunoassays. Tumor Biol. 2001, 22, 269-272.
122. Norum, L. F.; Sauren, A. M.; Rye, P. D.; Nustad, K. New immunoassays for MUC1 in breast cancer. Tumour Biol. 2001, 22, 216-222.
123. Hughes, O. D. M.; Perkins, A. C.; Frier, M.; Wastie, M. L.; Denton, G.; Price, M. R.; Denley, H.; Bishop, M. C. Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595. BJU Int. 2001, 87, 39-46.
124. Simms, M. S.; Murray, A.; Denton, G.; Scholfield, D. P.; Price, M. R.; Perkins, A. C.; Bishop, M. C. Production and characterisation of a C595 antibody-99mTc conjugate for immunoscintigraphy of bladder cancer. Urol. Res. 2001, 29, 13-19.
125. Moore, A.; Medarova, Z.; Potthast, A.; Dai, G. In vivo targeting of underglycosylated MUC1 tumor antigen using a multimodal imaging prob. Cancer Res. 2004, 64, 1821-1827.
126. Josephson, L.; Tung, C. H.; Moore, A.; Weissleder, R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug. Chem. 1999, 10, 186-191.
127. Josephson, L.; Kircher, M. F.; Mahmood, U.; Tang, Y.; Weissleder, R. Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug. Chem. 2002, 13, 554-560.
128. Medarova, Z.; Pham, W.; Kim, Y.; Dai, G.; Moore, A. In vivo imaging of tumor response to therapy using adual-modality imaging strategy. Int. J. Cancer 2006, 118, 2796-2802.
129. Ho, S. B.; Niehans, G. A.; Lyftogt, Y.; Yan, P. S.; Cherwitz, D. L.; Gum, E. T.; Dahiya, R.; Kim, Y. S. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993, 53, 641-651.
130. Zhang, S.; Zhang, H. S.; Reuter, V. E.; Slovin, S. F.; Scher, H. I.; Livingston, P. O. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin. Cancer Res. 1998, 4, 295-302.
131. Kirschenbaum, A.; Itzkowitz, S. H.; Wang, J. P.; Yao, S.; Eliashvili, M.; Levine, A. C. MUC1 expression in prostate carcinoma: correlation with grade and stage. Mol. Urol. 1999, 3, 163-168.
132. Schut, I. C.; Waterfall, P. M.; Ross, M.; O'Sullivan, C.; Miller, W. R.; Habib, F. K.; Bayne, C. W. MUC1 expression, splice variant and short form transcription (MUC1/Z, MUC1/Y) in prostate cell lines and tissue. BJU Int. 2003, 91, 278-283.
133. Arai, T.; Fujita, K.; Fujime, M.; Irimura, T. Expression of sialylated MUC1 in prostate cancer: Relationship to clinical stage and prognosis. Int. J. Urol. 2005, 12, 653-661.
134. O'Connor, J. C.; Julian, J.; Lim, S. D.; Carson, D. D. MUC1 expression in human prostate cancer cell lines and primary tumors. Prostate Cancer Prostatic. Dis. 2005, 8, 36-44.
135. Zellweger, T.; Ninck, C.; Bloch, M.; Mirlacher, M.; Koivisto, P. A.; Helin, H. J.; Mihatsch, M. J.; Gasser, T. C.; Bubendorf, L. Expression patterns of potential therapeutic targets in prostate cancer. Int. J. Cancer 2005, 113, 619-628.
136. DeNardo, S. J.; Richman, C. M.; Albrecht, H.; Burke, P. A.; Natarajan, A.; Yuan, A.; Gregg, J. P.; O'Donnell, R. T.; DeNardo, G. L. Enhancement of the therapeutic index: From nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer. Clin. Cancer Res. 2005, 11(Suppl 19), 7187s-7194s.
137. Goldenberg, D. M. Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. 2002, 43, 693-713.
138. Goldenberg, D. M. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol. Immunother. 2003, 52, 281-296.
139. Price, M. R.; Pugh, J. A.; Hudecz, F.; Griffiths, W.; Jacobs, E.; Symonds, I. M.; Clarke, A. J.; Chan, W. C.; Baldwin, R. W. C595- a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. Br. J. Cancer 1990, 61, 681-686.
140. Li, Y.; Russell, P. J.; Allen, B. J. Targeted alpha therapy for control of micrometastatic prostate cancer. Expert Rev. Anticancer Ther. 2004, 4, 89-98.
141. Li, Y.; Rizvi, S. M. A.; Brown, J. M.; Cozzi, P. J.; Qu, C. F.; Kim, O. W.; Tam, P.; Perkins, A. C.; Russell, P. J.; Allen, B. J. Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple targeted alpha-therapy with 213Bi-conjugates. Int. J. Radiat. Oncol. Biol. Phys. 2004, 60, 896-908.
142. Wang, J.; Rizvi, S. M. A.; Madigan, M. C.; Cozzi, P. J.; Power, C. A.; Qu, C. F.; Morgenstern, A.; Apostolidis, C.; Russell, P. J.; Allen, B. J.; Li, Y. Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted ? radioimmunoconjugates. Prostate 2006, 166, 1753-1767.
143. O'Donnell, R. T.; DeNardo, S. J.; Yuan, A.; Shen, S.; Richman, C. M.; Lara, P. N.; Griffith, I. J.; Goldstein, D. S.; Kukis, D. L.; Martinez, G. S.; Mirick, G. R.; DeNardo, G. L.; Meyers, F. J. Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin. Cancer Res. 2001, 7, 1561-1568.
144. Jaffee, E. M.; Thomas, M. C.; Huang, A. Y.; Hauda, K. M.; Levitsky, H. I.; Pardoll, D. M.Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J. Immunother. Emphasis. Tumor Immunol. 1996, 19, 176-183.
145. Guan, H. H.; Budzynski, W.; Koganty, R. R.; Krantz, M. J.; Reddish, M. A.; Rogers, J. A.; Longenecker, B. M.; Samuel, J. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug. Chem. 1998, 9, 451-458.
146. North, S.; Butts, C. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev. Vaccines 2005, 4, 249-257.
147. Barnd, D. L.; Lan, M. S.; Metzgar, R. S.; Finn, O. J. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA 1989, 86, 7159-7163.
148. Brossart, P.; Heinrich, K. S.; Stuhler, G.; Behnke, L.; Reichardt, V. L.; Stevanovic, S.; Muhm, A.; Rammensee, H. G.; Kanz, L.; Brugger, W. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999, 93, 4309-4317.
149. Scholl, S. M.; Balloul, J. M.; Le Goc, G.; Bizouarne, N.; Schatz, C.; Kieny, M. P.; von Mensdorff-Pouilly, S.; Vincent-Salomon, A.; Deneux, L.; Tartour, E.; Fridman, W.; Pouillart, P.; Acres, B. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J. Immunother. 2000, 23, 570-580.
150. Wajchman, H. J.; Pierce, C. W.; Varma, V. A.; Issa, M. M.; Petros, J.; Dombrowski, K. E. Ex vivo expansion of CD8+CD56+ and CD8+CD56-natural killer T cells specific for MUC1 mucin. Cancer Res. 2004, 64, 1171-1180.
151. Sharpe, J. C.; Abel, P. D.; Gilbertson, J. A.; Brawn, P.; Foster, C. S. Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium. Br. J. Urol. 1994, 74, 609-616.
152. Blades, R. A.; Keating, P. J.; McWilliam, L. J.; George, N. J.; Stern, P. L. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995, 46, 681-686.
153. Pantuck, A. J.; van Ophoven, A.; Gitlitz, B. J.; Tso, C. L.; Acres, B.; Squiban, P.; Ross, M. E.; Belldegrun, A. S.; Figlin, R. A. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J. Immunother. 2004, 27, 240-253.
154. Sutter, G.; Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 1992, 89, 10847-10851.
155. Liu, M.; Acres, B.; Balloul, J. M.; Bizouarne, N.; Paul, S.; Slos, P.; Squiban, P. Gene-based vaccines and immunotherapeutics. Proc. Natl. Acad. Sci. USA 2004, 101(suppl 2), 14567-14571.
156. Rochlitz, C.; Figlin, R.; Squiban, P.; Salzberg, M.; Pless, M.; Herrmann, R.; Tartour, E.; Zhao, Y.; Bizouarne, N.; Baudin, M.; Acres, B. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J. Gene. Med. 2003, 5, 690-699.